Advertisement
Annals
Established in 1927 by the American College of Physicians
:
Advanced search

Cover Image   
box In this Issue
  arrow Articles
  arrow Improving Patient Care
  arrow Academia and Clinic
  arrow Clinical Guidelines
  arrow Editorials
  arrow On Being a Doctor
  arrow Letters
  arrow Ad Libitum
  arrow Ancillary Content
  arrow Summaries for Patients
  arrow ACP Journal Club
  arrow PDF of Contents
box Services
  arrow Subscribe
  arrow One-time access
  arrow Activate online subscription
  arrow Access Personal Archive
 
box In this Issue
  arrow Articles
  arrow Improving Patient Care
  arrow Academia and Clinic
  arrow Clinical Guidelines
  arrow Editorials
  arrow On Being a Doctor
  arrow Letters
  arrow Ad Libitum
  arrow Ancillary Content
  arrow Summaries for Patients
  arrow ACP Journal Club
  arrow PDF of Contents
box Services
  arrow Subscribe
  arrow One-time access
  arrow Activate online subscription
  arrow Access Personal Archive
 

TABLE OF CONTENTS

18 November 2008 Volume 149 Issue 10
< Previous Issue  |  Next Issue >
Clear

Articles Back

Dick Menzies, Richard Long, Anete Trajman, Marie-Josée Dion, Jae Yang, Hamdan Al Jahdali, Ziad Memish, Kamran Khan, Michael Gardam, Vernon Hoeppner, Andrea Benedetti, and Kevin Schwartzman

Nine-month isoniazid treatment of latent tuberculosis infection is hepatotoxic and is complicated by poor patient adherence. Menzies and colleagues compared the frequency of adverse events and treatment completion between 4-month rifampin therapy and 9-month isoniazid therapy among 847 patients randomly assigned to either treatment. Patients who took rifampin had fewer adverse events and were more likely to complete treatment. The investigators did not compare efficacy of the 2 treatments, so their data justify a larger trial to compare the efficacy of these 2 treatments for latent tuberculosis infection.

Abstract | Full Text | PDF | CME

Susan R. Kahn, Ian Shrier, Jim A. Julian, Thierry Ducruet, Louise Arsenault, Marie-José Miron, Andre Roussin, Sylvie Desmarais, France Joyal, Jeannine Kassis, Susan Solymoss, Louis Desjardins, Donna L. Lamping, Mira Johri, and Jeffrey S. Ginsberg

Chronic leg symptoms after deep venous thrombosis (DVT) (the postthrombotic syndrome) are common but difficult to predict. By using a standardized scale, Kahn and coworkers evaluated leg symptoms in 387 patients for 2 years after DVT. Mild, moderate, and severe postthrombotic syndrome occurred in 30%, 10%, and 3% of patients, respectively, at all study intervals, but severity fluctuated over time in many patients. Age, previous DVT, and severity at 1 month were the best predictors of long-term severity.

Abstract | Full Text | PDF

Khalida Ismail, Stephen M. Thomas, Esther Maissi, Trudie Chalder, Ulrike Schmidt, Jonathan Bartlett, Anita Patel, Christopher M. Dickens, Francis Creed, and Janet Treasure

Psychological issues can interfere with management of type 1 diabetes. Ismail and colleagues examined whether psychological therapy might improve diabetes control. They compared motivational enhancement therapy with and without cognitive behavior therapy with usual care in 344 adults with type 1 diabetes (average baseline hemoglobin A1c level, 9.4%). Motivational enhancement therapy plus cognitive behavior therapy achieved a greater decrease in hemoglobin A1c over 12 months than did usual care (difference between groups, –0.46%). No other improvements were observed.

Abstract | Full Text | PDF | Summary for Patients


Improving Patient Care Back

Larry R. Churchill and David Schenck

Physicians' relationships with their patients can have healing effects, but the skills required are understudied. Churchill and Schenck interviewed 50 allopathic and alternative medicine practitioners identified by peers. Eight skills emerged as pivotal: do the little things; take time; be open and listen; find something to like, to love; remove barriers; let the patient explain; share authority; and be committed.

Abstract | Full Text | PDF


Academia and Clinic Back

Holly Janes, Margaret S. Pepe, and Wen Gu

Risk stratification tables evaluate the benefit of adding a new risk marker to a risk prediction model that includes an established set of markers. Janes and colleagues show how to use the tables to compare models with and without the new marker for 3 important measures of model performance. They discuss how the tables are an improvement over commonly reported measures of risk prediction model performance.

Abstract | Full Text | PDF


Clinical Guidelines Back

Amir Qaseem, Vincenza Snow, Thomas D. Denberg, Mary Ann Forciea, Douglas K. Owens for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians

This guideline presents current evidence on second-generation antidepressant treatment during the acute, continuation, and maintenance phases of major depressive disorder, dysthymia, subsyndromal depression, and accompanying symptoms. The American College of Physicians recommends that clinicians select second-generation antidepressants on the basis of adverse effect profiles, cost, and patient preferences. Clinicians should assess patient status, therapeutic response, and adverse effects of therapy on a regular basis beginning within 1 to 2 weeks of therapy initiation and should modify treatment if no adequate response to therapy is observed within 6 to 8 weeks of the therapy initiation. Treatment should continue for 4 to 9 months after a satisfactory response in patients with a first episode or for even longer in patients who have had 2 or more episodes.

Abstract | Full Text | PDF | Summary for Patients | Video News Release | CME

Gerald Gartlehner, Bradley N. Gaynes, Richard A. Hansen, Patricia Thieda, Angela DeVeaugh-Geiss, Erin E. Krebs, Charity G. Moore, Laura Morgan, and Kathleen N. Lohr

The authors reviewed the evidence of the benefits and harms of second-generation antidepressants for the treatment of depressive disorders in adults. They found that second-generation antidepressants did not substantially differ in efficacy or effectiveness (on the basis of 203 studies), but the incidence of specific adverse events and the onset of action did differ. The evidence is insufficient to draw conclusions about the comparative efficacy, effectiveness, or harms of these agents for the treatment of dysthymia and subsyndromal depression.

Abstract | Full Text | PDF | Summary for Patients | Video News Release


Editorials Back

Henry M. Blumberg

Poor acceptance and adherence to treatment regimens for latent tuberculosis infection (LTBI) are common. In this issue, Menzies and colleagues found that grade 3 to 4 hepatotoxicity was significantly less common among patients randomly assigned to 4 months of rifampin therapy than among those randomly assigned to 9 months of isoniazid therapy. Patients in the rifampin group were also more likely to complete treatment. The authors rightly conclude that a large-scale trial is indicated to assess the efficacy of rifampin monotherapy for the treatment of LTBI.

Full Text | PDF


On Being a Doctor Back

David B. Seder

Sitting down, looking strangers in the eye, and talking about death is part of the poetry of critical care. At first I thought that I had a talent for these discussions—that they were something others avoided that I could do. But that isn't quite right. In fact, these are opportunities for performance, and I seek them out like strong coffee or difficult procedures.

Full Text | PDF

Andrea A. Peterson

When I sit down on the side of the bed, I know. He has pale blue eyes and a careworn face, and I know that I will not make it home for dinner. I speak slowly and say, "On the CT scan, there are multiple abnormal spots in your liver." A pause, then: "It looks like the cancer has spread."

Full Text | PDF


Letters Back

What Conclusions Should Be Drawn between Critical Care Physician Management and Patient Mortality in the Intensive Care Unit?

    Thomas L. Higgins, Brian Nathanson, and Daniel Teres

    Full Text | PDF

    Andrew A. Quartin, Roland M.H. Schein, and Cynthia M. Cely

    Full Text | PDF

    Constantine Manthous and Yaw Amoateng-Adjepong

    Full Text | PDF

    Paul Marik, John Myburgh, Djillali Annane, Jean-Louis Vincent, Stephen Pastores, G. Umberto Meduri, and Albertus Beishuizen

    Full Text | PDF

    Mitchell M. Levy, John Rapoport, Stan Lemeshow, Gary Phillips, Donald B. Chalfin, and Marion Danis—RESPONSE

    Full Text | PDF

ADVANTAGE: Science First, Marketing Second

    Kevin P. Hill, David S. Egilman, and Harlan M. Krumholz—RESPONSE

    Full Text | PDF

ADVANTAGE: Merck Does Say "No"

    Harold C. Sox and Drummond Rennie—RESPONSE

    Full Text | PDF

The Vanderbilt Method for Resolving Unprofessional Behavior



Ad Libitum Back

Clayton J. Baker

Full Text | PDF


Ancillary Content Back

Full Text


Summaries for Patients Back

Full Text | PDF

Full Text | PDF | Video News Release


ACP Journal Club Back
The Best New Evidence for Patient Care

PDF

PDF

PDF

PDF

PDF

PDF

PDF

PDF

PDF

PDF

PDF

PDF

PDF

PDF



 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2009 by the American College of Physicians.